source
- Novartis' experimental heart drug pelacarsen fails pivotal Phase 3 trialNovartis announced that its experimental cardiovascular therapy, pelacarsen, did not meet its primary endpoints in the Phase 3 HORIZON trial. The study compared the drug to placebo and found no red…
- Ionis secures FDA approval for zilganersen, its first solo neurology therapy for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has granted approval to its investigational RNA‑based drug zilganersen for the treatment of Alexander disease, a rare neur…